P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

P21-activated kinase 1 regulates resistance to BRAF inhibition in human cancer cells

Published:2017-02-23 Issue:5 Volume:56 Page:1515-1525
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Mol. Carcinog.

Author:

Babagana Mahamat¹,Johnson Sydney¹,Slabodkin Hannah¹,Bshara Wiam²,Morrison Carl²,Kandel Eugene S.¹

Affiliation:

1. Department of Cell Stress Biology; Roswell Park Cancer Institute; Elm and Carlton Streets; Buffalo New York

2. Department of Pathology; Roswell Park Cancer Institute; Elm and Carlton Streets; Buffalo New York

Funder

Roswell Park Alliance Foundation, Roswell Park Cancer Institute

Jennifer Linscott Tietgen Family Foundation

National Institutes of Health

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Reference67 articles.

1. BRAF-mutant hematopoietic malignancies;Abdel-Wahab;Oncotarget,2014

2. Vemurafenib: the first drug approved for BRAF-mutant cancer;Bollag;Nat Rev Drug Discov,2012

3. BRAF inhibitors in cancer therapy;Hertzman Johansson;Pharmacol Ther,2014

4. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

5. A landscape of driver mutations in melanoma;Hodis;Cell,2012

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PAK1 and Therapy Resistance in Melanoma;Cells;2023-09-28

2. miR-224–5p acts as a tumour suppressor and reverses the resistance to BRAF inhibitor in melanoma through directly targeting PAK4 to block the MAPK pathway;Pathology - Research and Practice;2023-09

3. Hyperactivation of p21-Activated Kinases in Human Cancer and Therapeutic Sensitivity;Biomedicines;2023-02-05

4. Immune Checkpoint Inhibitors and RAS–ERK Pathway-Targeted Drugs as Combined Therapy for the Treatment of Melanoma;Biomolecules;2022-10-26

5. PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer;Cell Death & Disease;2022-07-28

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3